We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+6.31%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$852M
AUM Growth
+$151M
Cap. Flow
+$154M
Cap. Flow %
18.03%
Top 10 Hldgs %
46.73%
Holding
164
New
33
Increased
26
Reduced
31
Closed
28

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$28.9M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$14.6M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$9.62M
4
FOLD
Amicus Therapeutics
FOLD
+$9.34M
5
PRTA icon
Prothena Corp
PRTA
+$7.38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$18.6M
2
BIIB icon
Biogen
BIIB
+$9.88M
3
ITRN icon
Ituran Location and Control
ITRN
+$8.27M
4
ORBK
Orbotech Ltd
ORBK
+$6.41M
5
ZGNX
Zogenix, Inc.
ZGNX
+$5.08M

Sector Composition

Rank Sector Weight
1 Healthcare 58.93%
2 Technology 3.62%
3 Communication Services 2.25%
4 Financials 1.01%
5 Consumer Discretionary 0.94%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
$165M 19.42%
1,950,000
+550,000
+39% +$46.1M
IBB icon
2
PUT
iShares Biotechnology ETF
IBB
$9.34B
$53.4M 6.26%
+500,000
New +$53.4M
CELG
3
DELISTED
Celgene Corp
CELG
$32.2M 3.78%
309,000
+34,000
+12% +$3.84M
VTRS icon
4
Viatris
VTRS
$20.4B
$32M 3.76%
+756,449
New +$28.9M
MRK icon
5
Merck
MRK
$322B
$23.9M 2.81%
445,400
– –
BIIB icon
6
Biogen
BIIB
$30B
$23.6M 2.77%
74,200
-30,800
-29% -$9.88M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.57B
$21.4M 2.51%
384,997
– –
GSK icon
8
GSK
GSK
$104B
$16M 1.87%
360,000
– –
FOLD
9
DELISTED
Amicus Therapeutics
FOLD
$15.8M 1.86%
1,100,000
+680,000
+162% +$9.34M
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
$14.4M 1.68%
+120,000
New +$14.6M
PFE icon
11
Pfizer
PFE
$143B
$14.1M 1.66%
411,060
– –
CEL
12
DELISTED
Cellcom Israel, Ltd.
CEL
$14M 1.65%
1,359,744
-176,244
-11% -$1.71M
SHPG
13
DELISTED
Shire pic
SHPG
$13.4M 1.57%
86,500
– –
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$121B
$12.9M 1.51%
85,823
+65,000
+312% +$9.62M
CLVS
15
DELISTED
Clovis Oncology, Inc.
CLVS
$10.7M 1.26%
158,000
– –
PTLA
16
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$10.2M 1.2%
210,000
+65,000
+45% +$3.29M
NICE icon
17
Nice
NICE
$5.79B
$9.91M 1.16%
107,870
-1,289
-1% -$110K
CLLS
18
Cellectis
CLLS
$277M
$9.89M 1.16%
339,367
-9,369
-3% -$255K
AGN
19
DELISTED
Allergan plc
AGN
$9.81M 1.15%
60,000
– –
RXDX
20
DELISTED
Ignyta, Inc.
RXDX
$9.19M 1.08%
344,300
-115,000
-25% -$1.87M
VKTX icon
21
Viking Therapeutics
VKTX
$3.7B
$8.71M 1.02%
2,145,300
+1,855,300
+640% +$5.39M
TSRO
22
DELISTED
TESARO, Inc.
TSRO
$7.87M 0.92%
95,000
+15,000
+19% +$1.47M
PRTA icon
23
Prothena Corp
PRTA
$425M
$7.68M 0.9%
205,000
+145,000
+242% +$7.38M
LJPC
24
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.24M 0.85%
225,000
+75,000
+50% +$2.45M
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$7.13M 0.84%
17,049
-293
-2% -$105K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q4 2017 Portfolio in Review

As of Q4 2017, Sphera Funds Management held 164 positions worth $852M, up 22% from $701M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Sphera Funds Management deployed $154M of net new capital in Q4 2017, opening 33 new positions and adding to 26 existing holdings. Its largest new stake was Viatris: 756,449 shares worth $32M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 63% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Biogen, an estimated $9.88M trimmed.

  • Sphera Funds Management's largest Q4 2017 buy was Viatris: 756,449 shares worth $32M.
  • Sphera Funds Management added most to Vertex Pharmaceuticals in Q4 2017, an estimated $9.62M increase.
  • Sphera Funds Management's biggest Q4 2017 reduction was Biogen, cutting an estimated $9.88M.
  • Sphera Funds Management fully exited Gilead Sciences in Q4 2017, selling an estimated $18.6M.
  • Sphera Funds Management's ten largest holdings make up 47% of its $852M portfolio in Q4 2017.
  • Sphera Funds Management opened 33 new positions and closed 28 in Q4 2017.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $852M.

Based on Sphera Funds Management's 13F filing for Q4 2017, filed 12 Feb 2018.